Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Silexion Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Silexion Therapeutics's regulatory disclosures and financial reporting.
Silexion Therapeutics Corp disclosed that three reporting persons—Intracoastal Capital, LLC, Mitchell P. Kopin and Daniel B. Asher—may each be deemed to beneficially own 244,771 ordinary shares, representing 9.99% of the class as of close of business on September 17, 2025. The filing explains these shares arise primarily from warrants issued under a Securities Purchase Agreement and notes multiple warrants include blocker provisions that limit exercise to prevent ownership above 9.99% (and 4.99% for one warrant). Voting and dispositive power over the 244,771 shares is reported as shared rather than sole.
Orca Capital AG reported beneficial ownership of 109,432 ordinary shares of Silexion Therapeutics Corp, representing 4.9% of the outstanding class based on 2,123,892 shares outstanding after the issuer's registered offering. The filing clarifies that the reporting person also holds warrants for 153,068 ordinary shares but cannot exercise them to the extent doing so would increase beneficial ownership above 4.99% (the "4.99% Blocker"). Orca states the securities were not acquired to change or influence control of the issuer and reports sole voting and dispositive power over the reported shares.